Nonetheless, the results of the meta-analysis (Figure 9) confirmed the significant relationship between FASN expression and the outcomes for breast cancer, liver cancer, lung cancer, and gastric cancer (P < 0.05) but not for ovarian cancer (P = 0.998). The gene discussed is FASN; the disease is lung carcinoma.